NASDAQ:CYTHW Cyclo Therapeutics (CYTHW) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free CYTHW Stock Alerts $0.24 -0.05 (-17.34%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.24▼$0.2550-Day Range$0.23▼$0.3352-Week Range$0.13▼$0.50Volume3,160 shsAverage Volume2,368 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestSocial Media Get Cyclo Therapeutics alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Cyclo TherapeuticsCyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.Read More CYTHW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTHW Stock News HeadlinesJune 29, 2023 | businesswire.comCyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1June 29, 2023 | finance.yahoo.comCyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1See More Headlines Receive CYTHW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:CYTHW CUSIPN/A CIK922247 WebN/A Phone386-418-8060FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.08 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. N. Scott Fine (Age 67)CEO & Director Comp: $877.88kMr. C. E Strattan (Age 78)Founder & Director Comp: $44kMr. Joshua M. Fine (Age 42)CFO & Secretary Comp: $509.38kMr. Michael Eric Lisjak (Age 51)Chief Regulatory Officer & Senior VP of Business Development Comp: $505.9kDr. Jeffrey L. Tate Ph.D. (Age 66)COO, Chief Quality Officer & Director Comp: $255.14kMs. Lori McKennaGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical OfficerMore ExecutivesKey CompetitorsAlvotechNASDAQ:ALVOWBiofronteraNASDAQ:BFRIWClever LeavesNASDAQ:CLVRWProcaps GroupNASDAQ:PROCWSunshine BiopharmaNASDAQ:SBFMWView All Competitors CYTHW Stock Analysis - Frequently Asked Questions How have CYTHW shares performed in 2024? Cyclo Therapeutics' stock was trading at $0.28 on January 1st, 2024. Since then, CYTHW shares have decreased by 14.9% and is now trading at $0.2384. View the best growth stocks for 2024 here. Are investors shorting Cyclo Therapeutics? Cyclo Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 500 shares, a decline of 28.6% from the February 29th total of 700 shares. Based on an average trading volume of 1,500 shares, the short-interest ratio is presently 0.3 days. View Cyclo Therapeutics' Short Interest. How do I buy shares of Cyclo Therapeutics? Shares of CYTHW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTHW) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.